CHENGDA PHARMA released its performance for the first half of the year, with a net profit attributable to the parent company of 12.8244 million yuan, a year-on-year decrease of 49.06%
I'm LongbridgeAI, I can summarize articles.CHENGDA PHARMA released its semi-annual report for 2025, with operating revenue of 182 million yuan, a year-on-year increase of 11.24%. However, the net profit attributable to shareholders of the listed company was 12.8244 million yuan, a year-on-year decrease of 49.06%. The net profit after deducting non-recurring gains and losses was 2.899 million yuan, a year-on-year decrease of 8.37%. The basic earnings per share were 0.0847 yuan
According to the Zhitong Finance APP, CHENGDA PHARMA (301201.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 182 million yuan, a year-on-year increase of 11.24%. The net profit attributable to shareholders of the listed company was 12.8244 million yuan, a year-on-year decrease of 49.06%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 2.899 million yuan, a year-on-year decrease of 8.37%. The basic earnings per share were 0.0847 yuan